Salivary cortisol during opiate dependence and withdrawal
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Seventeen inpatients (14 men, three women) with opiate dependence and polysubstance misuse participated in a longitudinal study of salivary cortisol secretion during and after lofexidine detoxification treatment. Both opiate withdrawal symptoms and salivary cortisol were measured every morning for up to 25 days. Results were compared with a control group of 10 normal volunteers. There was an 80% reduction in withdrawal symptom severity between the first 12 days and the subsequent 12 days of treatment. Salivary cortisol fell from a mean of 22.3 nm/l over days 1–12 to 18.5 nm/l during days 13–25, a reduction of 17%. Salivary cortisol concentration correlated significantly with withdrawal symptom severity. Salivary cortisol levels remained significantly higher than controls for the duration of the study. The study supports a role for hypothalamo–pituitary–adrenal (HPA) activation in opiate withdrawal. The contribution of persistant dysregulation of the HPA, found in this study, to the vulnerability for relapse after abstinence has been achieved, is discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For opioids, individuals with OUD, when subjected to acute withdrawal from heroin and methadone, exhibited persistent elevations of cortisol levels (Culpepper-Morgan and Kreek, 1997;Bearn et al., 2001), and cortisol levels correlated with withdrawal severity (Bearn et al., 2001).”
From Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development (2021) · cites this paper as Bearn et al., 2001
In the citing paper
“Whereas, acutely, opioid receptor agonists inhibit the HPA axis, opioid withdrawal potently activates it (Culpepper-Morgan and Kreek, 1997;Bearn et al., 2001).”
From Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development (2021) · cites this paper as Bearn et al., 2001
In the citing paper
“In OUD, the importance of the anti-reward system during the withdrawal state is supported by the evidence that cortisol levels are suppressed in patients with active opioid use (36–38), and then elevated in response to opioid withdrawal upon cessation (39–42).”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [42]
In the citing paper
“HPA axis dysregulation may persist well beyond the initial acute withdrawal phase, with one study demonstrating that salivary cortisol levels were significantly higher in OUD patients compared with controls for at least 25 days after detoxification (42).”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [42]
Citations
Cites
Drug dependence: stress and dysregulation of brain reward pathways
Kreek, M. J., & Koob, G. F. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00064-7 · Cited by 696
Piazza, P. V., & Le Moal, M. (1996) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.002043 · Cited by 690
Corticosterone levels determine individual vulnerability to amphetamine self-administration.
Piazza, P. V., Maccari, S., Deminière, J. M., Le Moal, M., Mormède, P., & Simon, H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.6.2088 · Cited by 574
Endocrine Effects of Naloxone-Induced Opiate Receptor Blockade *
MORLEY, J. E., BARANETSKY, N. G., WINGERT, T. D., CARLSON, H. E., HERSHMAN, J. M., MELMED, S., LEVIN, S. R., JAMISON, K. R., WEITZMAN, R., CHANG, R. J., et al. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-50-2-251 · Cited by 300
The development of a short opiate withdrawal scale (SOWS)
Gossop, M. (1990) · Addictive Behaviors · doi:10.1016/0306-4603(90)90036-w · Cited by 261
Martin, W. R., & Jasinski, D. R. (1969) · Journal of Psychiatric Research · doi:10.1016/0022-3956(69)90007-7 · Cited by 259
Heinrichs, S. C., Menzaghi, F., Schulteis, G., Koob, G. F., & Stinus, L. (1995) · Behavioural Pharmacology · doi:10.1097/00008877-199501000-00011 · Cited by 226
Wolff, K., Farrell, M., Marsden, J., Monteiro, M. G., Ali, R., Welch, S., & Strang, J. (1999) · Addiction · doi:10.1046/j.1360-0443.1999.94912792.x · Cited by 181
Siever, L. J., & Uhde, T. W. (1984) · PubMed · Cited by 156
Marinelli, M., Piazza, P., Deroche, V, Maccari, S., Le Moal, M., & Simon, H. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-05-02724.1994 · Cited by 133
Research works printed but not linked: 4
- Pheterson A, 1983, Plasma cortisol levels in opiate addicts before and after detoxification, Proc Soc Neurose, 417
- Kirschbaum C, 1992, Assessment of hormones and drugs in saliva in biobehavioural research, 19
- Rosen MI, 1996, Effects of clonidine pre‐treatment on naloxone‐precipitated opiate withdrawal, J Pharm Exp Ther, 276, 1128
- Kreek MJ., 1992, Addictive states, 205
Cited by
Brunner, E. J., Hemingway, H., Walker, B. R., Page, M., Clarke, P., Juneja, M., Shipley, M. J., Kumari, M., Andrew, R., Seckl, J. R., et al. (2002) · Circulation · doi:10.1161/01.cir.0000038364.26310.bd · Cited by 539
“... 3.8) 0.007 Serum amyloid A, mg/L 147:29 2.55 (2.0, 3.2) 3.10 (2.2, 4.3) 0.26 3.25 (2.3, 4.7) 0.19 Plasma fibrinogen, g/L 148:30 3.05 (2.9, 3.2) 3.18 (3.0, 3.4) 0.25 3.14 (2.9, 3.4) 0.59 Plasma D-dimer, ng/mL 153:30 40.1 (33, 49) 40.2 (30, 53) 0.98 46.0 (35, 61) 0.22 Plasma viscosity, mPas 149:30 1.23 (1.22, 1.25)…”
InfluentialSelf-citationDrug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development
Koob, G. F. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000083 · Cited by 337
“, 2001), and cortisol levels correlated with withdrawal severity (Bearn et al., 2001).”
BackgroundModeling withdrawal syndrome in zebrafish
Cachat, J., Canavello, P., Elegante, M., Bartels, B., Hart, P., Bergner, C., Egan, R., Duncan, A., Tien, D., Chung, A., et al. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.12.004 · Cited by 189
“Withdrawal-evoked nxiety strongly correlates with elevated blood or salivary cortisol n patients with heroin [44,59], opioid [6,73], nicotine [12], cocaine 24] and ethanol [37,50] addiction.”
BackgroundZebrafish models to study drug abuse-related phenotypes
Stewart, A., Wong, K., Cachat, J., Gaikwad, S., Kyzar, E. J., Wu, N., Hart, P. C., Piet, V., Utterback, E., Elegante, M. F., et al. (2011) · Reviews in the Neurosciences · doi:10.1515/rns.2011.011 · Cited by 158
“Similar to the response observed in both humans (Bearn et al. , 2001 ; Fox et al. , 2009 ; Shi et al. , 2009 ) and rodents (Borlikova et al. , 2006 ; Rabbani et al. , 2009 ), withdrawal elevates zebrafi sh cortisol, correlating with the expected higher levels of stress and anxiety (Cachat et al. ,…”
ResultCraving in Opioid Use Disorder: From Neurobiology to Clinical Practice
Kakko, J., Alho, H., Baldacchino, A., Molina, R., Nava, F. A., & Shaya, G. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00592 · Cited by 140
“HPA axis dysregulation may persist well beyond the initial acute withdrawal phase, with one study demonstrating that salivary cortisol levels were significantly higher in OUD patients compared with controls for at least 25 days after detoxification (42).”
Background
Metadata
- Authors
- Bearn, J., Buntwal, N., Papadopoulos, A., & Checkley, S.
- Corresponding author
- Bearn, J.
- ORCID
- Papadopoulos, A.
- Venue
- Addiction Biology
- Publisher
- Wiley
- Published
- 2001-04
- Volume
- 6
- Issue
- 2
- Pages
- 157-162
- ISSN
- 1355-6215 (ISSN-L)
- 1369-1600
- OpenAlex
- W2014644687
- Cited by
- 42
- References
- 21
- Citations by year
- 2025: 7 · 2024: 2 · 2023: 5 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 3 · 2016: 2 · 2015: 1 · 2014: 3
- FWCI
- 0.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Addiction Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- salivary cortisol, opioid use disorder, opioid withdrawal, lofexidine, detoxification, hypothalamic-pituitary-adrenal axis, withdrawal symptom severity, relapse vulnerability, abstinence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Salivary cortisol during opiate dependence and withdrawal. https://app.cochat.ai/papers/10.1080/13556210020040235
- The paper
- Bearn, J., Buntwal, N., Papadopoulos, A., & Checkley, S. (2001). Salivary cortisol during opiate dependence and withdrawal. Addiction Biology. https://doi.org/10.1080/13556210020040235
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.